| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
President and CEO | Director
3 companies
Martha Goldberg Aronson is President and CEO at MMSI, with reported holdings spanning 3 companies. The disclosed holdings are worth an estimated $3.3M at current prices.
Martha Goldberg Aronson's largest disclosed position is in MMSI as President and CEO, worth about $3.0M. Net of sales, the MMSI filings show accumulation of 2,000 shares.
Martha Goldberg Aronson has 20 Form 4 filings on record from February 2016 to May 2026, across 3 companies: President and CEO at Merit Medical Systems (MMSI), 2025–2026; Director at Conmed (CNMD), 2016–2025; Director at Methode Electronics (MEI), 2016–2019.
The 39 reported transactions were 21 option or other derivative awards, 10 option exercises, 6 stock awards and 2 open-market purchases.
Counted by filing, the open-market trades come to 2 purchases worth about $263K and no sales.
The largest open-market purchase was 2,000 shares of CNMD at an average $70.98 on May 6, 2024, about $142K. Twelve months later CNMD was down 21%.